Today: 30 January 2026
Subscribe
Browse Category

Lawsuits News 30 September 2025 - 4 December 2025

Coca-Cola (KO) Stock Outlook December 2025: Dividend King Faces Lawsuit Risk but Analysts Still See Upside

Coca-Cola (KO) Stock Outlook December 2025: Dividend King Faces Lawsuit Risk but Analysts Still See Upside

Data and news current through the close on December 4, 2025. This article is for informational purposes only and is not investment advice. Coca-Cola stock today: price, performance and valuation The Coca-Cola Company (NYSE: KO) closed at $70.54 on December 4, 2025, down about 0.37% for the day. Intraday, shares traded between $70.45 and $71.34 on volume of roughly 8.4…
4 December 2025
····
Synopsys (SNPS) Stock on December 3, 2025: Nvidia’s $2 Billion Bet, Class‑Action Lawsuits and New Analyst Forecasts

Synopsys (SNPS) Stock on December 3, 2025: Nvidia’s $2 Billion Bet, Class‑Action Lawsuits and New Analyst Forecasts

Synopsys, Inc. (NASDAQ: SNPS) is back in the market spotlight after a volatile few months. On Wednesday, December 3, 2025, the stock extended a sharp rebound driven by Nvidia’s $2 billion strategic investment, even as fresh class‑action lawsuits and mixed analyst messages kept risks firmly on the radar. As of the U.S. close on December 3, Synopsys shares were trading…
3 December 2025
···
Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

On December 2, 2025, Bristol-Myers Squibb (NYSE: BMY) found itself at the center of two very different storylines: a revived $6.7 billion Celgene lawsuit and strong hematology data at ASH 2025. Together with a hefty dividend and low valuation multiples, these cross-currents are shaping how investors see BMY stock heading into 2026. BMY Stock Snapshot on 2 December 2025 On…
3 December 2025
····
Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (NYSE: BMY) has suddenly become one of the most eventful big pharma names to watch as of December 1, 2025. A major lawsuit has been allowed to proceed, new cell therapy approvals are landing, hematology data at ASH 2025 is impressive, and investors are reassessing the stock’s value, dividend and medium‑term growth story. Below is a deep dive…
2 December 2025
····
Standard Chartered PLC Hit by US$2.7bn 1MDB Lawsuit as It Accelerates Capital, Green Finance and Digital-Asset Push – 24 November 2025

Standard Chartered PLC Hit by US$2.7bn 1MDB Lawsuit as It Accelerates Capital, Green Finance and Digital-Asset Push – 24 November 2025

On 24 November 2025, Standard Chartered PLC finds itself in a paradoxical position: facing a major legal challenge in Singapore linked to the 1MDB scandal, while simultaneously showcasing strength in capital, sustainability, and digital innovation across its key markets. From a US$2.7 billion lawsuit being allowed to proceed, to early compliance with Nigeria’s new capital rules, a Green Halal pilot…
24 November 2025
··
Uber Stock Poised to Soar? Guggenheim’s $140 Price Target Explained

Uber Stock Today, November 20, 2025: AI Pay Lawsuit Triggers Sell‑Off Despite Robot Delivery Deal

Uber Technologies (NYSE: UBER) had a volatile session on Thursday, 20 November 2025, as investors weighed a fresh European legal challenge to the company’s AI‑driven pay systems against upbeat news on automation, travel partnerships and still‑bullish Wall Street views. By late trade, UBER had fallen sharply in the regular session to the mid‑$80s, down roughly 6–7% on the day, with…
20 November 2025
····
Broadcom’s $10B AI Chip Deal Ignites Stock Surge – What’s Powering This Tech Giant’s Boom

Broadcom Stock Today (Nov. 20, 2025): AVGO Rallies on AI Launch, Nvidia Results and Fidelity Lawsuit

Broadcom Inc. (NASDAQ: AVGO) is back in the spotlight on Thursday, November 20, 2025, as the stock extends a sharp rebound driven by powerful AI infrastructure news, Nvidia’s blockbuster earnings, and rising legal drama around VMware. On Wednesday, AVGO jumped about 4.1% to close near $354, with trading volume above 21 million shares. Investing Pre‑market quotes early Thursday showed another ~3% gain, pushing…
20 November 2025
····
Beyond Meat (BYND) Stock Skyrockets 50% Amid Meme Mania – Turnaround or Dead Cat Bounce?

Beyond Meat Stock Crashes to $1 as Shareholders Face Massive Dilution and Lawsuit Risks – 19 November 2025

Published: 19 November 2025 Beyond Meat’s dramatic late‑October meme‑stock rally has given way to a brutal reality check. On 19 November 2025, the plant‑based meat pioneer is trading around $1 per share, down roughly 40% just this month and about 73% year‑to‑date, hovering near penny‑stock territory and flirting with Nasdaq’s minimum bid‑price rules.  Stocktwits At the same time, shareholders are being asked to approve…
19 November 2025
··
Genius Group (GNS) Soars on Market‑Manipulation Lawsuit: What Today’s 17 November 2025 Rally Really Means

Genius Group (GNS) Soars on Market‑Manipulation Lawsuit: What Today’s 17 November 2025 Rally Really Means

Genius Group Limited (NYSE American: GNS) is back in the spotlight today after its stock spiked more than 35–40% in U.S. pre‑market trading, driven by fresh attention on a newly filed $250 million federal securities class action lawsuit against Citadel Securities and Virtu Americas. Stocktwits By midday, the move has cooled but GNS is still trading around $0.86, up modestly…
17 November 2025
····
Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Kenvue (KVUE) Stock Plummets to Record Low Amid Talc Lawsuit and Tylenol Scare

Stock Hits a 52-Week Low on Legal Woes Kenvue’s shares collapsed to an all-time low since their mid-2023 IPO, closing around $14 after Thursday’s 13.2% plunge Stocktwits. The one-day drop – Kenvue’s worst on record – was triggered by headline risks that blindsided investors. By early Friday, October 17, the stock stabilized slightly (up about 0.6% in pre-market trading) after…
17 October 2025
····
Capital One Savers Cheated Out of Billions – $425M Settlement Payout Deadline Fast Approaching

Capital One Savers Cheated Out of Billions – $425M Settlement Payout Deadline Fast Approaching

Capital One’s $425 million settlement stems from a years-long fight over alleged bait-and-switch tactics. The crux of the case is that Capital One promoted its “360 Savings” account as a top high-yield product, yet kept its rate locked at about 0.30% even as national rates climbed. At the same time, the bank quietly introduced a nearly identical “360 Performance Savings” account,…
30 September 2025
··
1 2 3 4

Stock Market Today

  • Exxon Mobil Q4 Earnings Beat Estimates but Revenue Misses
    January 30, 2026, 9:42 AM EST. Exxon Mobil (XOM) reported Q4 earnings of $1.71 per share, surpassing the Zacks Consensus Estimate of $1.68, marking a 1.99% earnings surprise. Revenues stood at $82.31 billion, missing estimates by 1.05% and falling short of last year's $83.43 billion. The company has beaten earnings estimates consistently over the past four quarters but has missed revenue targets in the same period. Exxon shares have gained 16.8% year-to-date, outperforming the S&P 500's 1.8% rise. The stock's near-term direction depends on upcoming management commentary and revisions to earnings projections. Currently holding a Zacks Rank #3 (Hold), Exxon is expected to perform in line with the market. Investors will watch for updates to consensus EPS and revenue estimates amid a weak industry ranking for Oil and Gas - Integrated - International.
Go toTop